Skip to main content
Erschienen in: Familial Cancer 2/2019

24.09.2018 | Original Article

Development and pilot testing of a leaflet informing women with breast cancer about genomic testing for polygenic risk

verfasst von: Rajneesh Kaur, Bettina Meiser, Tatiane Yanes, Mary-Anne Young, Kristine Barlow-Stewart, Tony Roscioli, Sian Smith, Paul A. James

Erschienen in: Familial Cancer | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

The inclusion of polygenic risk scores in breast cancer risk prediction models provides a more personalised and accurate prediction of breast cancer risk for women with and without breast cancer, who would otherwise receive negative results from traditional testing of moderate- and high-risk genes. This study aimed to develop, and pilot test a leaflet with a sample of women participating in a large prospective cohort study. The leaflet aimed to provide information about polygenic risk to assist women to decide whether or not to learn results from genomic testing for common risk variants associated with breast cancer risk. A prototype of the leaflet was developed based on published literature and with the expertise from a multidisciplinary team. The acceptability of the leaflet was assessed by self-report questionnaire among 29 women participating in the prospective cohort study. More than 80% participants stated that the leaflet was clear, informative and easy to understand and increased their understanding of polygenic risk information. While low to moderate levels of distress/worry were reported around implications of the test results for the next generation, 71% felt reassured and agreed that the information provided in the leaflet had helped them cope. Pilot-test results indicate the leaflet is acceptable to the participants and the revised leaflet can be used as an information tool for women undergoing genomic testing. This educational leaflet will become a useful information source to meet the information needs of women undergoing genomic testing.
Literatur
1.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRef
2.
Zurück zum Zitat Domchek S, Friebel T, Singer C (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. J Amer Med Assoc 304(9):967–975CrossRef Domchek S, Friebel T, Singer C (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. J Amer Med Assoc 304(9):967–975CrossRef
3.
Zurück zum Zitat Visvanathan K et al (2009) American Society of Clinical Oncology clinical practice guideline update on the use of pharmacological interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235–3258CrossRefPubMedPubMedCentral Visvanathan K et al (2009) American Society of Clinical Oncology clinical practice guideline update on the use of pharmacological interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235–3258CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Rebbeck T, Kauff N, Domchek S (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80–87CrossRefPubMedPubMedCentral Rebbeck T, Kauff N, Domchek S (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80–87CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Thompson D, Easton D (2004) The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 9(3):221–236CrossRefPubMed Thompson D, Easton D (2004) The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 9(3):221–236CrossRefPubMed
6.
Zurück zum Zitat Riley BD et al (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21(2):151–161CrossRefPubMed Riley BD et al (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21(2):151–161CrossRefPubMed
7.
Zurück zum Zitat Sawyer S et al (2012) A role for common genomic variants in the assessment of familial breast cancer. J Clin Oncol 30(35):4330–4336CrossRefPubMed Sawyer S et al (2012) A role for common genomic variants in the assessment of familial breast cancer. J Clin Oncol 30(35):4330–4336CrossRefPubMed
8.
Zurück zum Zitat Muranen TA et al (2016) Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families. Breast Cancer Res Treat 158(3):463–469CrossRefPubMedPubMedCentral Muranen TA et al (2016) Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families. Breast Cancer Res Treat 158(3):463–469CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Michailidou K et al (2015) Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet 47(4):373–380CrossRefPubMedPubMedCentral Michailidou K et al (2015) Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet 47(4):373–380CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Michailidou K et al (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45(4):353–361, 361e1–361e2CrossRefPubMedPubMedCentral Michailidou K et al (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45(4):353–361, 361e1–361e2CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Mavaddat N et al (2015) Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 107(5):1–15CrossRef Mavaddat N et al (2015) Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 107(5):1–15CrossRef
13.
Zurück zum Zitat Kuchenbaecker KB et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416CrossRefPubMed Kuchenbaecker KB et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416CrossRefPubMed
14.
Zurück zum Zitat Li H et al (2017) Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. Genet Med 19(1):30–35CrossRefPubMed Li H et al (2017) Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. Genet Med 19(1):30–35CrossRefPubMed
15.
Zurück zum Zitat Dite GS et al (2016) Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years: Australian breast cancer family registry. Cancer Epidemiol Biomark Prev 25:359–365CrossRef Dite GS et al (2016) Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years: Australian breast cancer family registry. Cancer Epidemiol Biomark Prev 25:359–365CrossRef
16.
Zurück zum Zitat Yanes T et al (2017) Psychosocial and behavioral impact of breast cancer risk assessed by testing for common risk variants: protocol of a prospective study. BMC Cancer 17(1):491CrossRefPubMedPubMedCentral Yanes T et al (2017) Psychosocial and behavioral impact of breast cancer risk assessed by testing for common risk variants: protocol of a prospective study. BMC Cancer 17(1):491CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Clerehan R, Buchbinder R, Moodie J (2005) A linguistic framework for assessing the quality of written patient information: its use in assessing methotrexate information for rheumatoid arthritis. Health Educ Res 20(3):334–344CrossRefPubMed Clerehan R, Buchbinder R, Moodie J (2005) A linguistic framework for assessing the quality of written patient information: its use in assessing methotrexate information for rheumatoid arthritis. Health Educ Res 20(3):334–344CrossRefPubMed
18.
Zurück zum Zitat Clerehan R, Hirsh D, Buchbinder R (2009) Medication information leaflets for patients: the further validation of an analytic linguistic framework. Commun Med 6(2):117–127PubMed Clerehan R, Hirsh D, Buchbinder R (2009) Medication information leaflets for patients: the further validation of an analytic linguistic framework. Commun Med 6(2):117–127PubMed
20.
Zurück zum Zitat Wakefield CE et al (2008) A randomized trial of a breast/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling. Psychooncology 17(8):844–854CrossRefPubMed Wakefield CE et al (2008) A randomized trial of a breast/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling. Psychooncology 17(8):844–854CrossRefPubMed
21.
Zurück zum Zitat Wakefield CE et al (2007) Development and pilot testing of two decision aids for individuals considering genetic testing for cancer risk. J Genet Couns 16(3):325–339CrossRefPubMed Wakefield CE et al (2007) Development and pilot testing of two decision aids for individuals considering genetic testing for cancer risk. J Genet Couns 16(3):325–339CrossRefPubMed
22.
Zurück zum Zitat Wakefield CE et al (2011) Development and pilot testing of an online screening decision aid for men with a family history of prostate cancer. Patient Educ Couns 83(1):64–72CrossRefPubMed Wakefield CE et al (2011) Development and pilot testing of an online screening decision aid for men with a family history of prostate cancer. Patient Educ Couns 83(1):64–72CrossRefPubMed
23.
Zurück zum Zitat McPherson CJ, Higginson IJ, Hearn J (2001) Effective methods of giving information in cancer: a systematic literature review of randomized controlled trials. J Public Health Med 23(3):227–234CrossRefPubMed McPherson CJ, Higginson IJ, Hearn J (2001) Effective methods of giving information in cancer: a systematic literature review of randomized controlled trials. J Public Health Med 23(3):227–234CrossRefPubMed
24.
Zurück zum Zitat Metcalfe A et al (2007) Psychosocial impact of the lack of information given at referral about familial risk for cancer. Psychooncology 16(5):458–465CrossRefPubMed Metcalfe A et al (2007) Psychosocial impact of the lack of information given at referral about familial risk for cancer. Psychooncology 16(5):458–465CrossRefPubMed
Metadaten
Titel
Development and pilot testing of a leaflet informing women with breast cancer about genomic testing for polygenic risk
verfasst von
Rajneesh Kaur
Bettina Meiser
Tatiane Yanes
Mary-Anne Young
Kristine Barlow-Stewart
Tony Roscioli
Sian Smith
Paul A. James
Publikationsdatum
24.09.2018
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 2/2019
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-018-0104-4

Weitere Artikel der Ausgabe 2/2019

Familial Cancer 2/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.